Last reviewed · How we verify
Vincristine and Topotecan
Vincristine is a vinca alkaloid that inhibits microtubule formation, while Topotecan is a topoisomerase I inhibitor that prevents DNA replication.
Vincristine is a vinca alkaloid that inhibits microtubule formation, while Topotecan is a topoisomerase I inhibitor that prevents DNA replication. Used for Acute lymphoblastic leukemia, Small cell lung cancer.
At a glance
| Generic name | Vincristine and Topotecan |
|---|---|
| Also known as | Oncovin + Hycamtin |
| Sponsor | St. Jude Children's Research Hospital |
| Drug class | Vinca alkaloid and topoisomerase I inhibitor |
| Target | Microtubules and topoisomerase I |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vincristine works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Topotecan, on the other hand, inhibits topoisomerase I, an enzyme that unwinds DNA during replication. By inhibiting this enzyme, Topotecan prevents DNA replication and induces apoptosis in cancer cells.
Approved indications
- Acute lymphoblastic leukemia
- Small cell lung cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (PHASE1)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma (PHASE3)
- A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT (PHASE2)
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vincristine and Topotecan CI brief — competitive landscape report
- Vincristine and Topotecan updates RSS · CI watch RSS
- St. Jude Children's Research Hospital portfolio CI